Surmodics, Inc. (NASDAQ:SRDX) posted its quarterly earnings data on Wednesday. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.19, Bloomberg Earnings reports. The firm had revenue of $20.06 million during the quarter, compared to the consensus estimate of $16.98 million. Surmodics had a net margin of 5.37% and a return on equity of 6.18%.

Shares of Surmodics (NASDAQ SRDX) traded up $0.15 during trading hours on Friday, hitting $30.00. 27,053 shares of the stock traded hands, compared to its average volume of 39,453. The firm has a market cap of $393.30, a PE ratio of 60.00 and a beta of 0.78. Surmodics has a one year low of $21.90 and a one year high of $32.80.

In other news, VP Joseph J. Stich sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $27.28, for a total value of $27,280.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.40% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Surmodics, Inc. (SRDX) Announces Earnings Results” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/surmodics-inc-srdx-announces-earnings-results/1694271.html.

SRDX has been the subject of a number of recent research reports. BidaskClub downgraded shares of Surmodics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. ValuEngine downgraded shares of Surmodics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, Lake Street Capital initiated coverage on shares of Surmodics in a report on Friday, July 14th. They issued a “buy” rating and a $40.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $40.00.

About Surmodics

Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.

Earnings History for Surmodics (NASDAQ:SRDX)

Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.